DFMO in recent-onset T1D: phase 1 safety study
What this study tests
A completed 41-person study of oral DFMO, a polyamine-synthesis inhibitor. It met its safety and tolerability endpoint and generated an exploratory C-peptide signal for later testing.
Editorial review: . What was checked and what remains uncertain.
Registry checked: 2026-09-16. Registry’s own update: 2021-09-05.
Latest dated source in the citation list: 2023-11-01. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence at a glance
- Who can enter the study?
- Ages 12–40, diagnosed 2–8 months earlier, random nonfasting C-peptide above 0.2 pmol/mL, at least one islet autoantibody and normal hearing at screening. The study is completed. Additional exclusion criteria appear in the registry. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- The 2023 paper reports 41 participants randomized approximately 3:1 and says the primary safety/tolerability endpoint was met. Higher-dose C-peptide findings were exploratory; this small study does not establish clinical efficacy. The registry has no posted results tables.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read this trial’s review notes for the checks completed and what remains unresolved. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Participants with dose-limiting toxicities over six months, including blood-count changes, severe gastrointestinal symptoms or hearing loss.
The full picture
What was studied
This early trial tested oral DFMO in people with recent-onset autoimmune T1D and measurable remaining insulin production. The registry lists 41 actual participants at three US sites, with study completion on 6 January 2020. Its primary endpoint concerns dose-limiting toxicities, including hearing loss, blood-count changes and severe gastrointestinal symptoms.1
Published findings
The 2023 paper describes three months of treatment followed by three months of observation. It reports 41 participants randomized approximately 3:1, a met safety/tolerability endpoint, and an exploratory signal for C-peptide preservation at higher doses. Those findings supported further investigation; they do not establish an effective T1D treatment or beta-cell regrowth in people.2
Registry discrepancy and next study
The older registry description proposes 2:1 randomization and labels the intervention model single-group, while the publication reports a randomized placebo-controlled 3:1 study. This page uses the publication for the conducted study and preserves that discrepancy. No tabular results are posted to the registry.12
The later TADPOL trial tests longer treatment. Its planned outcomes must not be presented as additional results from this phase 1 study.
References
-
ClinicalTrials.gov. NCT02384889. Checked 16 September 2026. https://clinicaltrials.gov/study/NCT02384889 ↩ ↩2
-
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes. https://pubmed.ncbi.nlm.nih.gov/37918404/ ↩ ↩2
Sources
- [1]DFMO in Children With Type 1 Diabetes · registry — Protocol and registry status checked 16 September 2026.
- [2]Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes · peer-reviewed · 2023-11-01